CD274 and non-small cell lung carcinoma: Intra‐ and inter‐tumoral heterogeneity of PD‐L1 expression has been observed in 78% and 53% of non‐small cell lung cancer (NSCLC) patients, respectively.[8] This variability contributes to inconsistent correlations between PD‐L1 expression levels and clinical outcomes following ICI treatment.[8] Moreover, tissue‐based analysis requires sufficiently high‐quality samples, which are often unavailable in advanced‐stage disease—highlighting the need for more reliable, accessible biomarkers.